Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial

被引:156
|
作者
Sokolove, Jeremy [1 ,2 ]
Schiff, Michael [3 ]
Fleischmann, Roy [4 ]
Weinblatt, Michael E. [5 ]
Connolly, Sean E. [6 ]
Johnsen, Alyssa [6 ]
Zhu, Jin [7 ]
Maldonado, Michael A. [6 ]
Patel, Salil [6 ]
Robinson, William H. [1 ,2 ]
机构
[1] Stanford Univ, Sch Med, VA Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA
[2] Stanford Univ, Sch Med, Div Rheumatol & Immunol, Palo Alto, CA 94304 USA
[3] Univ Colorado, Dept Rheumatol, Denver, CO 80202 USA
[4] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA
[5] Brigham & Womens Hosp, Dept Rheumatol & Immunol, Boston, MA 02115 USA
[6] Bristol Myers Squibb Co, Immunosci, Princeton, NJ USA
[7] Bristol Myers Squibb Co, Global Biometr Sci, Princeton, NJ USA
关键词
RHEUMATOID-ARTHRITIS; PROTEIN ANTIBODIES; NECROSIS-FACTOR; AUTOANTIBODIES; REMISSION; SAFETY; RA;
D O I
10.1136/annrheumdis-2015-207942
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives To examine whether baseline anti-cyclic citrullinated peptide-2 CCP2) antibody status and concentration correlated with clinical outcomes in patients treated with abatacept or adalimumab on background methotrexate MTX) in the 2-year AMPLE Abatacept versus adaliMumab comParison in bioLogic-naive rheumatoid arthritis subjects with background MTX) study. Methods In this exploratory analysis, anti-CCP2 antibody concentration was measured at baseline, and antibody-positive patients were divided into equal quartiles, Q1-Q4, representing increasing antibody concentrations. Clinical outcomes analysed by baseline anti-CCP2 status and quartile included change from baseline in disease activity and disability and remission rates. Results Baseline characteristics were generally comparable across quartiles and treatment groups. In both treatment groups, anti-CCP2 antibody-negative patients responded less well than antibody-positive patients. At year 2, improvements in disease activity and disability and remission rates were similar across Q1-Q3, but were numerically higher in Q4 in the abatacept group; in contrast, treatment effects were similar across all quartiles in the adalimumab group. Conclusions In AMPLE, baseline anti-CCP2 positivity was associated with a better response for abatacept and adalimumab. Patients with the highest baseline anti-CCP2 antibody concentrations had better clinical response with abatacept than patients with lower concentrations, an association that was not observed with adalimumab.
引用
收藏
页码:709 / 714
页数:6
相关论文
共 3 条
  • [1] Anti-cyclic citrullinated peptide antibody titer predicts time to rheumatoid arthritis onset in patients with undifferentiated arthritis: results from a 2-year prospective study
    Bizzaro, Nicola
    Bartoloni, Elena
    Morozzi, Gabriella
    Manganelli, Stefania
    Riccieri, Valeria
    Sabatini, Paola
    Filippini, Matteo
    Tampoia, Marilina
    Afeltra, Antonella
    Sebastiani, Giandomenico
    Alpini, Claudia
    Bini, Vittorio
    Bistoni, Onelia
    Alunno, Alessia
    Gerli, Roberto
    ARTHRITIS RESEARCH & THERAPY, 2013, 15 (01)
  • [2] Anti-cyclic citrullinated peptide antibody titer predicts time to rheumatoid arthritis onset in patients with undifferentiated arthritis: results from a 2-year prospective study
    Nicola Bizzaro
    Elena Bartoloni
    Gabriella Morozzi
    Stefania Manganelli
    Valeria Riccieri
    Paola Sabatini
    Matteo Filippini
    Marilina Tampoia
    Antonella Afeltra
    Giandomenico Sebastiani
    Claudia Alpini
    Vittorio Bini
    Onelia Bistoni
    Alessia Alunno
    Roberto Gerli
    Arthritis Research & Therapy, 15
  • [3] Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparatore-controlled VOYAGE 2 trial
    Reich, Kristian
    Armstrong, April W.
    Foley, Peter
    Song, Michael
    Wasfi, Yasmine
    Randazzo, Bruce
    Li, Shu
    Shen, Y. -K.
    Gordon, Kenneth B.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (03) : 418 - 431